All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science

Latest Review From US Agency Finds ‘Zero Difference’ In Risks When Switching

In meta-analyses of biosimilar switching studies, FDA researchers found “zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.”

No Difference - dictionary definition
The FDA found biosimilar switching produced “zero difference” in key risks • Source: Shutterstock

US Food and Drug Administration research highlighted by the agency’s Center for Drug Evaluation and Research in a “spotlight on CDER science” has concluded that switching between branded biologics and biosimilars produces “zero difference in the risk of death, serious adverse events, and treatment discontinuations between participants who switched between biosimilars and reference products and participants who did not switch.”

The project saw FDA researchers conduct a systematic review and meta-analysis using statistical methods to determine whether there were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By 

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Richter Sets Launch Timetable for Denosumab and Tocilizumab Biosimilars

 
• By 

Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

More from Products